The side effects that come with many cancer treatments can cause people to delay or avoid treatment.

Congruence secures a $5 million grant to advance innovative therapies for GBA1 Parkinson's disease, enhancing hope for ...

The acquisition led by Advent International will see the two AI-powered companies combine forces to improve the healthcare ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic ...

Unlock the secrets of executive presence in pharma to inspire confidence, influence decisions, and elevate your leadership ...

Global leader in mother and childcare, Philips Avent, announced a partnership with March of Dimes to establish the modern-day ...

A timeline of key developments surrounding Sarepta Therapeutics' Duchenne muscular dystrophy drug Elevidys, and the potential ...

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

With reports that FDA’s AI Elsa is “confidently hallucinating” studies that don’t exist, the use of AI to streamline drug review and speed up approval is not here yet.

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis’ potential to broaden its clinical impact ...

Biotech veteran and Stanford physician-scientist brings 30 years of translational research and regulatory experience to ...

A panel of industry leaders share key insights supporting the integration of patient-centric strategies into current and ...